Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC)

CAPS Rating: 3 out of 5

A development-stage biopharmaceutical company dedicated to the discovery, development and eventual commercialization of novel, mechanism-targeted drugs to treat human cancers and other serious disorders.

Recs

0
Player Avatar mdriver78 (57.68) Submitted: 1/7/2013 9:38:56 AM : Underperform Start Price: $5.79 CYCC Score: +41.65

Spike from announced review of Clinical achievements will decay as they will bleed cash through the Phase 3 trials for SEAMLESS for sapacitabine in elderly patients with newly diagnosed acute myeloid leukemia (AML), our lead indication, and they exceeded 100 patients enrolled with 37 trial sites open. The plan for 2013 seems to indicate a good list of potential drugs, but cash flow will hender the share price.

Featured Broker Partners


Advertisement